.Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CX04_Miltefosine.Miltefosine

Information

Miltefosine is an alkylphosphocholine drug that was originally developed as an anticancer agent, but is currently approved and primarily used for the oral treatment of leishmaniasis (visceral, cutaneous, and mucocutaneous), a neglected tropical protozoal disease. It is the first effective oral drug for leishmaniasis and is included in WHO’s Essential Medicines List.

Pharmacokinetics

Population pharmacokinetic parameters in adult Indian patients with visceral leishmaniasis following standard oral dosing.

References

1. Ramisetty, BS, et al., & Wang, MZ (2024). Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach. Antimicrobial agents and chemotherapy 68(7) e0032824–None. DOI:10.1128/aac.00328-24 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38842325

2. Berman, J (2005). Miltefosine to treat leishmaniasis. Expert opinion on pharmacotherapy 6(8) 1381–1388. DOI:10.1517/14656566.6.8.1381 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16013987

3. Sundar, S, et al., & Berman, J (2003). Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. The Pediatric infectious disease journal 22(5) 434–438. DOI:10.1097/01.inf.0000066877.72624.cb PUBMED:https://pubmed.ncbi.nlm.nih.gov/12792385

Revisions

• 06/2025 initial generated model